Form 4: Cytek Biosciences SVP Allen Poirson Reports Stock Transactions

Allen Poirson, SVP of Business and Corporate Development at Cytek Biosciences, reports transactions involving common stock and restricted stock units.

Summary

• On August 19, 2024, Allen Poirson, SVP of Business and Corporate Development at Cytek Biosciences, executed transactions involving the company's common stock and restricted stock units (RSUs).
• Poirson acquired shares through the vesting of RSUs and disposed of shares to cover tax withholding obligations.
• The transactions resulted in a net change in Poirson's beneficial ownership of Cytek Biosciences common stock.
• Following the reported transactions, Poirson directly owns 56,825 shares of common stock.
• Poirson also holds 26,926 restricted stock units.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing, so the sentiment is neutral.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. This filing indicates the transactions of a key executive at Cytek Biosciences.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in insider ownership.
• The transactions have no direct impact on employees, customers, suppliers, or creditors.

Key Dates